Gain Therapeutics Inc. Revenue 2020–2023
Gain Therapeutics Inc. annual/quarterly revenue history and growth rate from 2020 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Gain Therapeutics Inc. revenue for the quarter ending March 31, 2023 was 55180, a 47.00% increase year-over-year.
- Gain Therapeutics Inc. revenue for the twelve months ending March 31, 2023 was 203791, a 103.88% increase year-over-year.
- Gain Therapeutics Inc. annual revenue for 2023 was 55180, a 58.40% decrease from 2022.
- Gain Therapeutics Inc. annual revenue for 2022 was 132640, a 0.96% decrease from 2021.
- Gain Therapeutics Inc. annual revenue for 2021 was 133928, a 363.72% increase from 2020.
- Gain Therapeutics Inc. annual revenue for 2020 was 28881.
Gain Therapeutics Inc. (GANX) — Frequently Asked Questions
Gain Therapeutics Inc. (GANX) is a publicly traded US company. It has a market capitalization of $21M. In fiscal 2023 it reported revenue of $55,180 and net income of -$22M. Explore GANX's stock price, financial statements, earnings history, margins and key ratios below.
What is Gain Therapeutics Inc.'s market cap?
Gain Therapeutics Inc. (GANX) has a market capitalization of $21M.
What is the GANX stock price?
GANX trades at $1.64 (-0.61% on the day).
How much revenue does Gain Therapeutics Inc. make?
Gain Therapeutics Inc. reported revenue of $55,180 in fiscal 2023.
Is GANX profitable?
In fiscal 2023, Gain Therapeutics Inc. reported net income of -$22M.